PATENT CLAIM ANALYSIS

Application Number: 16061974
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "314000"]

Abstract:
The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.

Claim (Index 1):
A composition comprising:\n (a) X4P-001, or a pharmaceutically acceptable salt thereof\u2014about 30-40% by weight of the composition; (b) microcrystalline cellulose\u2014about 20-25% by weight of the composition; (c) dibasic calcium phosphate dihydrate\u2014about 30-35% by weight of the composition; (d) croscarmellose sodium\u2014about 5-10% by weight of the composition; (e) sodium stearyl fumarate\u2014about 0.5-2% by weight of the composition; (f) colloidal silicon dioxide\u2014about 0.1-1.0% by weight of the composition; and (g) sodium lauryl sulfate\u2014about 0.1-1.0% by weight of the composition.

Metadata:
- Claim Count in Document: 49.0
- Percentile: 94.0
- Lexical Diversity: 1.29787
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12937630', '15553570', '15805390', '14905776', '12671287']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7136650481069257
- 35 USC 102 Novelty (BERT): 0.4932681727074532
- Combined Prediction Score: 0.6916253605669784
- Mean Citation Score: 186.025422
- Max Citation Score: 194.66278
- Similarity Product: 142.6937197624588

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test